Abstract
Psoriasis is the only disease in dermatology where biologics have been studied in placebo controlled trials. However, drugs have been used for several other indications in dermatology, e.g. pyoderma gangrenosum and pemphigus. We give a brief overview of the indications for biologics in skin diseases.
MeSH terms
-
Acne Vulgaris / drug therapy
-
Acne Vulgaris / pathology
-
Adalimumab
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents / therapeutic use*
-
Behcet Syndrome / drug therapy
-
Behcet Syndrome / pathology
-
Dermatologic Agents / therapeutic use*
-
Etanercept
-
Humans
-
Immunoglobulin G / therapeutic use
-
Immunologic Factors / therapeutic use*
-
Infliximab
-
Interferons / therapeutic use
-
Lymphoma, T-Cell, Cutaneous / drug therapy
-
Lymphoma, T-Cell, Cutaneous / pathology
-
Pemphigus / drug therapy
-
Pemphigus / pathology
-
Pyoderma Gangrenosum / drug therapy
-
Pyoderma Gangrenosum / pathology
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Rituximab
-
Skin Diseases / drug therapy*
-
Skin Diseases / pathology
-
Skin Neoplasms / drug therapy
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antineoplastic Agents
-
Dermatologic Agents
-
Immunoglobulin G
-
Immunologic Factors
-
Receptors, Tumor Necrosis Factor
-
Rituximab
-
Interferons
-
Infliximab
-
Adalimumab
-
Etanercept
-
efalizumab